Abbott Laboratories Form 4 insider transactions

Philip P. Boudreau, Executive Vice President of Abbott Laboratories, reports a transaction involving common shares on September 1, 2024.

John A. McCoy, Jr., a Vice President at Abbott Laboratories, reported the disposition of company stock to cover tax obligations and a sale of shares.

Louis H. Morrone, Executive Vice President of Abbott Laboratories, reports the disposal of common shares to cover tax obligations.

Director John G. Stratton reports acquiring 353 stock equivalent units of Abbott Laboratories on June 30, 2024, at a price of $103.91 per unit.

Director Michael F. Roman reports acquisition of stock equivalent units in Abbott Laboratories due to director fees.

Director Patricia Paola Gonzalez reports acquisition of 317 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.

Director Robert J. Alpern acquired 75 stock equivalent units of Abbott Laboratories on June 30, 2024, through director fees credited to a grantor trust.

Robert E. Funck, Jr., Executive Vice President of Abbott Laboratories, reports the exercise of stock options and subsequent sale of shares on May 10, 2024.

Lisa D. Earnhardt, Executive Vice President of Abbott Laboratories, sold 22,852 common shares at an average price of $106.2541 on May 7, 2024.

Director John G. Stratton reports acquisition and disposal of Abbott Laboratories common shares and restricted stock units.

Director Daniel J. Starks reports acquisition of restricted stock units and stock options in Abbott Laboratories under the 2017 Incentive Stock Program.

Director Michael F. Roman reports acquisition of 1,866 restricted stock units of Abbott Laboratories, convertible to common shares upon certain events.

Director Michael O'Grady reports acquisition of restricted stock units and stock options in Abbott Laboratories under the 2017 Incentive Stock Program.

Director Nancy McKinstry reports acquisition of Abbott Laboratories common shares and stock options under the company's incentive stock program.

Director Darren W. McDew acquired 1,866 common shares of Abbott Laboratories through restricted stock units on April 26, 2024.

Director Michelle Kumbier reports acquisition of restricted stock units and disposal of common shares of Abbott Laboratories.

Patricia Paola Gonzalez, a director of Abbott Laboratories, reported the acquisition of 1,866 restricted stock units on April 26, 2024.

Director Sally E. Blount reports acquisition of 1,866 restricted stock units of Abbott Laboratories, increasing her holdings to 35,023 common shares.

Director Claire Babineaux-Fontenot acquired 1,866 common shares of Abbott Laboratories through a restricted stock unit award under the company's 2017 Incentive Stock Program.

Director Robert Alpern reports acquisition of 1,866 common shares of Abbott Laboratories on April 26, 2024, through restricted stock units.

Director John G. Stratton reports acquiring 323 stock equivalent units of Abbott Laboratories on March 31, 2024, through director fees credited to a grantor trust.

Director Michael F. Roman reports acquisition of Abbott Laboratories stock equivalent units through director fees.

Director Patricia Paola Gonzalez reports acquisition of 290 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.

Director Robert J. Alpern reports acquisition of 69 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.

Andrea F. Wainer, Executive Vice President of Abbott Laboratories, reported disposing of 8,339 common shares on February 29, 2024.

Executive Vice President Daniel Gesua Sive Salvadori reports the disposition of Abbott Laboratories shares to cover tax obligations and a sale of shares on March 1, 2024.

Executive Vice President Louis H. Morrone of Abbott Laboratories reports the disposition of shares and updates to beneficial ownership.

Executive Vice President Mary K. Moreland reports the disposition and acquisition of Abbott Laboratories common shares, including shares withheld for tax obligations and shares sold on the open market.

Abbott Laboratories' Vice President, John A. McCoy, Jr., reports the disposition and acquisition of company stock, including sales to cover tax obligations.

Robert E. Funck, Jr., Executive Vice President of Abbott Laboratories, reports the disposal of 11,415 common shares to cover tax obligations.